Key result
Elevated Lp(a) is linked to ~2% higher thromboembolism risk in nonvalvular atrial fibrillation.
Why the study?
Although patients with low CHA2DS2-VASc score have a low risk of thromboembolism and anticoagulant therapy is not recommended, many still suffer thrombotic events and stroke, necessitating investigation of additional risk factors.
Observational (n=595)
High lipoprotein (a) levels (>27.2 mg/dL) and left atrial dilatation (>43.5 mm) are independent risk factors for thrombotic events in NVAF patients with low CHA2DS2-VASc scores, potentially identifying a subset at higher risk despite current guidelines not recommending anticoagulation.
Answers are grounded in this paper and cite their sources.
Highlights residual stroke risk in low CHA2DS2-VASc NVAF; leaves open whether identified factors warrant anticoagulation or need prospective validation.
The risk of thromboembolism in patients with CHA2DS2-VASc score of 0 to 1 was low, and the anticoagulant therapy was not recommended. Although the CHA2DS2-VASc score was low, there were still many patients suffered from thrombotic events and stroke. We aim to investigate the risk factors of thrombotic events in nonvalvular atrial fibrillation (NVAF) patients with low CHA2DS2-VASc score.We retrospectively enrolled 595 consecutive NVAF patients with low CHA2DS2-VASc score (male: CHA2DS2-VASc = 0, female: CHA2DS2-VASc = 1). The general clinical data, blood biochemical data, and echocardiography results of the 595 patients were collected. Multivariate logistic regression models were used to evaluate risk factors of thrombosis. Receiver operating characteristic curve was used to identify the optimal cut-off value of the independent risk factors. A P value of <.05 (2-sided) was considered to be statistically significant.In multivariate analysis, lipoprotein (a) (Lp(a)) plasma level and left atrium diameter (LAD) were positively related to thromboembolism in NVAF patients with CHA2DS2-VASc score of 0 to 1 after adjustment for age, gender, and other variables (odds ratio [OR] = 1.02, 95% confidence interval [CI]: 1.01-1.03; OR = 1.13, 95% CI: 1.06-1.18). Lp(a) exerted a significant predictive value with area under the curve (AUC) of 0.62 (95% CI: 0.55-0.68, P < .01). The optimal cut-off value for Lp(a) predicting thrombotic events was 27.2 mg/dL (sensitivity 45.7%, specificity 73.4%). LAD showed a significant predictive value with AUC of 0.71 (95% CI: 0.64-0.78, P < .01). The optimal cut-off point for LAD predicting thrombotic events was 43.5 mm (sensitivity 47.1%, specificity 85.8%).High Lp(a) plasma level and left atrial dilatation might be independent risk factors of thrombotic events for NVAF patients with low CHA2DS2-VASc score.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2019) conducted an observational in Nonvalvular atrial fibrillation (NVAF) with low CHA2DS2-VASc score (n=595). Lipoprotein (a) plasma level and left atrium diameter was evaluated on Thromboembolism (OR 1.02, 95% CI 1.01-1.03). High Lipoprotein (a) plasma levels and left atrial diameter were independent risk factors for thromboembolism in NVAF patients.
Synapse has enriched 10 related papers. Consider them for comparative context: